Health Economics & Insurance Policies Department, Dubai Health Authority, Dubai, UAE.
Health & Value and Patient Outcomes, Pfizer, Dubai, UAE.
PLoS One. 2021 Sep 1;16(9):e0256856. doi: 10.1371/journal.pone.0256856. eCollection 2021.
Pneumonia is a significant cause of morbidity and mortality among adults globally. This retrospective cohort analysis assessed the pneumonia burden and related healthcare resource utilization and costs in the at-risk (low, medium, and high-risk) adult patients in Dubai, United Arab Emirates (UAE).
The claims data from January 1, 2014 to June 30, 2019 were extracted from the Dubai Real-World Claims Database for patients, aged ≥18 year, having at least 1 pneumonia claim. Data for the inpatient, outpatient and emergency visits were assessed for 12-months, before (pre-index) and after (follow-up) a pneumonia episode. Healthcare costs were calculated based on dollar value of 2020.
Total 48,562 records of eligible patients were analyzed (mean age = 39.9 years; low [62.1%], medium [36.2%] and high [1.7%] risk cohorts). Mean all-cause healthcare costs were approximately >45% higher in the follow-up period (1,947 USD/patient) versus pre-index period (1,327 USD/patient). During follow-up period, the mean annual pneumonia incidence rate was 1.3 episodes, with a similar pattern across all cohorts. Overall, mean claims and costs (USD) per patient (all-cause) were highest in the high-risk cohort in the follow-up period (claims: overall, 11.6; high-risk, 22.0; medium-risk, 13.9; low-risk, 9.9; costs: high-risk, 14,184; medium-risk, 2,240; low-risk, 1,388). Similarly, the mean pneumonia-related costs (USD) per patient were highest for the high-risk cohort (overall: 1,305; high-risk, 10,207; medium-risk, 1,283; low-risk, 882), however, the claims were similar across cohorts (claims/patient: overall: 2.0; high-risk, 1.9; medium-risk, 2.2; low-risk, 1.9). Most all-cause and pneumonia-related costs were due to inpatient visits (4,901 and 4,818 USD respectively), while outpatient (1,232 and 166 USD respectively) and emergency visits (347 and 206 USD respectively) contributed significantly lesser.
Pneumonia imposes a significant healthcare burden in the UAE, especially in the high-risk patients with severe comorbidities. These findings would guide clinicians and policy makers to make informed decisions.
肺炎是导致全球成年人发病和死亡的重要原因。本回顾性队列分析评估了在阿联酋迪拜高风险(低、中、高风险)成年患者中肺炎的负担以及相关的医疗资源利用和成本。
从 2014 年 1 月 1 日至 2019 年 6 月 30 日,从迪拜真实世界索赔数据库中提取了至少有 1 例肺炎索赔的年龄≥18 岁的患者的数据。在肺炎发作前(索引前)和后(随访)的 12 个月内,评估了住院、门诊和急诊就诊的数据。根据 2020 年的美元价值计算医疗保健费用。
共分析了 48562 例符合条件的患者记录(平均年龄为 39.9 岁;低[62.1%]、中[36.2%]和高[1.7%]风险队列)。随访期间的全因医疗保健费用平均比索引前时期(1327 美元/患者)高出约 45%(1947 美元/患者)。在随访期间,所有队列的平均年度肺炎发病率均为 1.3 例,模式相似。总体而言,在随访期间,高风险队列的每位患者(全因)的平均索赔和费用(美元)最高(索赔:总体、11.6;高风险、22.0;中风险、13.9;低风险、9.9;费用:高风险、14184;中风险、2240;低风险、1388)。同样,每位患者的肺炎相关费用(美元)也以高风险队列最高(总体:1305;高风险、10207;中风险、1283;低风险、882),但各队列的索赔相似(患者/索赔:总体:2.0;高风险、1.9;中风险、2.2;低风险、1.9)。所有全因和肺炎相关费用主要来自住院(分别为 4901 美元和 4818 美元),而门诊(分别为 1232 美元和 166 美元)和急诊就诊(分别为 347 美元和 206 美元)的贡献则明显较小。
肺炎在阿联酋造成了重大的医疗保健负担,尤其是在患有严重合并症的高风险患者中。这些发现将指导临床医生和政策制定者做出明智的决策。